- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
First patient treated in Phase I UCART19 trial in paediatric B-ALL
21 June 2016 • Author: Victoria White, Digital Content Producer
Cellectis has announced that the first patient has been treated in the Phase I study of UCART19 in paediatric acute B lymphoblastic leukaemia (B-ALL) at the University College of London (UCL).
This UCART19 clinical trial is sponsored by Servier in close collaboration with Pfizer.
The paediatric Phase I study will evaluate the safety and ability of UCART19 to induce molecular remission in paediatric patients with relapsed or refractory CD19 positive acute B-ALL ahead of planned allogeneic haematopoeitic stem cell transplantation (allo-HSCT).
Cellectis will receive a milestone payment from Servier of an undisclosed amount.
Servier and Pfizer collaborate on UCART19
UCART19 is an allogeneic CAR T-cell product candidate developed for treatment of CD19-expressing hematological malignancies, gene edited with Talen. UCART19 is initially being developed in chronic lymphocytic leukaemia (CLL) and acute lymphoblastic leukaemia (ALL). Cellectis’ approach with UCART19 is based on the preliminary positive results from clinical trials using autologous products based on the CAR technology, and has the potential to overcome the limitation of the current autologous approach by providing an allogeneic, frozen, “off-the-shelf” T cell based medicinal product.
In November last year, Great Ormond Street Hospital (GOSH) used UCART19 cells to treat a one-year-old girl who had relapsed ALL. GOSH reported the patient as cancer free and doing well.
In November 2015, Servier acquired the exclusive rights to UCART19 from Cellectis. Following further agreements, Servier and Pfizer began collaborating on a joint clinical development programme for this cancer immunotherapy. Pfizer has exclusive rights from Servier to develop and commercialise UCART19 in the United States, while Servier retains exclusive rights for all other countries.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics